SCHEMBL4692980

SCHEMBL4692980

O=C1Cc2ccccc2N1c1cc(Cl)cc(Cl)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.69
CASP6 P55212 5/20 0.51
OPRK1 P41145 1/20 0.46
PDE4D Q08499 1/20 0.46
GAA P10253 6/20 0.44
KMT2A Q03164 6/20 0.44
MEN1 O00255 5/20 0.44
PKM P14618 1/20 0.44
TLR9 Q9NR96 1/20 0.44
NOTUM Q6P988 1/20 0.44
TNKS O95271 1/20 0.43
CASP3 P42574 2/20 0.43
SENP8 Q96LD8 2/20 0.43
SENP7 Q9BQF6 2/20 0.43
SENP6 Q9GZR1 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
DRD2 P14416 2/20 0.42
DRD5 P21918 1/20 0.42
DRD3 P35462 1/20 0.42
DRD4 P21917 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6763292 0.87 HPGD (0.70) HPGDCASP6OPRK1PDE4DGAA
SCHEMBL6327688 0.86 HPGD (0.74) HPGDCASP6OPRK1PDE4DGAA
SCHEMBL31422646 0.82 HPGD (1.00) HPGDCASP6OPRK1PDE4DGAA
SCHEMBL143970 0.82 HPGD (1.00) HPGDCASP6OPRK1PDE4DGAA
SCHEMBL11133610 0.79 HPGD (0.62) HPGDCASP6GAAKMT2AMEN1
SCHEMBL10398760 0.77 OPRK1 (0.65) HPGDCASP6OPRK1PDE4DGAA
SCHEMBL16110543 0.77 OPRK1 (0.65) HPGDCASP6OPRK1PDE4DGAA
SCHEMBL16456324 0.76 HPGD (0.74) HPGDCASP6GAAKMT2AMEN1
SCHEMBL4463146 0.76 HPGD (0.74) HPGDCASP6GAAKMT2AMEN1
SCHEMBL2982634 0.76 GAA (0.59) HPGDCASP6GAAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1399155-B1 SMALL MOLECULES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASE BOEHRINGER INGELHEIM PHARMA (US) 2008-05-28 EP disclosed
US-6414153-B1 TREATMENT OF INFLAMMATORY OR IMMUNE CELL-MEDIATED DISEASE OR CONDITION BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2002-07-02 US disclosed